nucleoside naive patients

Related by string. * nucleosides . Nucleoside : nucleoside analogues alone . nucleoside analogue . cycle modulating nucleoside . nucleoside analogues / NAIVE . Naive : Blanche DuBois naive . treatment naive genotype . naive HCV genotype . refractory rituximab naive / pa tients . PATIENTS . PATIENT . Patients : Breast Cancer Patients . terminally ill patients . Patient Safety * *

Related by context. Frequent words. (Click for all words.) 62 androgen deprivation 62 CMV disease 61 virologic failure 61 virologic 60 noninferiority 60 chemoradiotherapy 60 secondary efficacy endpoints 60 virologic response 60 active comparator 59 plus gemcitabine 59 RRMS patients 59 CMV infection 59 NRTI 59 febrile neutropenia 59 mcg dose 59 Fidaxomicin 59 sustained virologic response 59 NNRTIs 59 prespecified 59 placebo controlled clinical 59 nitazoxanide 58 thromboembolic events 58 cytogenetic response 58 decitabine 58 achieved statistical significance 58 chronic HCV infection 58 plus dexamethasone 58 lymphopenia 58 complete remissions 58 tolerated dose MTD 58 dose limiting toxicities 58 adalimumab 58 dacarbazine 57 adefovir 57 tipranavir 57 dose regimens 57 mg kg dose 57 peginterferon alfa 2a 57 mg QD 57 entecavir 57 undetectable viral load 57 Secondary endpoints included 57 mycophenolate mofetil 57 lymph node involvement 57 antiviral activity 57 administered subcutaneously 57 neoadjuvant therapy 57 dose regimen 57 axitinib 57 neoadjuvant chemotherapy 57 fibrinolysis 57 cytotoxic chemotherapy 57 plus methotrexate 57 viremia 57 seroconversion 57 systemic absorption 56 PROMACTA 56 sensitivity specificity 56 temsirolimus 56 NNRTI 56 renal dysfunction 56 tanespimycin 56 anticoagulation therapy 56 HCV infected 56 distant metastasis 56 NEUMUNE 56 cabazitaxel 56 HER2 positive metastatic breast 56 REMICADE ® 56 Secondary endpoints 56 prospective randomized controlled 56 abiraterone acetate 56 neoadjuvant 56 certolizumab pegol 56 rHuPH# 56 mg BID 56 Amrubicin 56 FOLFOX 56 azacitidine 55 diagnosed multiple myeloma 55 antitumor activity 55 bisphosphonate therapy 55 sunitinib 55 interferon alfa 55 peginterferon 55 confidence interval #.#-#.# 55 elagolix 55 aflibercept 55 coinfected 55 Combination therapy 55 annualized relapse 55 double blinded placebo 55 hypercalcemia 55 XELOX 55 metastatic renal cell carcinoma 55 mitoxantrone 55 viral suppression 55 DMARD 55 relapsed refractory multiple myeloma 55 d4T 55 evaluable

Back to home page